Computed tomography findings of hepatic veno-occlusive disease caused by Sedum aizoon with histopathological correlation

Shao, Hui; Chen, H. Z.; Zhu, Jingjing; Ruan, Bing; Zhang, Z. Q.; Lin, Xianfeng; Gan, Meifu

doi:10.1590/1414-431x20154563

Cited by 19 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In rats, the first pathological changes involve damage to the microscopic anatomy of hepatic sinusoid endothelial cells, followed by the development of hepatic sinusoid obstruction, endothelial cell damage, and impaired integrity of sinusoid walls, with hepatic sinusoid congestion in hepatic acinus zone III . Obvious hepatic plate damage, hepatic cell necrosis, interlobular vein endothelial cell injury, and lobular wall swelling are shown in Figure . On day 6 after the development of the monocrotaline‐induced model, normal hepatic pathology may be nearly restored in some rats.…”

Section: Pathologymentioning

confidence: 99%

“…The typical computed tomography (CT) findings include diffuse hepatomegaly, and plain scans reveal heterogeneous decreased density of the hepatic parenchyma. Enhancement is characterized by a map‐like or mottle‐like nonhomogeneous appearance in the venous phase and equilibrium phase and a low‐density area of edema, that is, a halo sign around the portal vein.…”

Section: Imaging Studiesmentioning

confidence: 99%

“…21 Obvious hepatic plate damage, hepatic cell necrosis, interlobular vein endothelial cell injury, and lobular wall swelling are shown in Figure 1. 15,[21][22][23] On day 6 after the development of the monocrotaline-induced model, normal hepatic pathology may be nearly restored in some rats. In others, hepatic cell injury improves, but deposition of collagen in perisinusoidal spaces of Disse and interlobular veins persists.…”

Section: Pathologymentioning

confidence: 99%

See 2 more Smart Citations

Expert consensus on the clinical management of pyrrolizidine alkaloid‐induced hepatic sinusoidal obstruction syndrome

Zhuge

Liu

Zou

et al. 2019

J of Gastro and Hepatol

127

View full text Add to dashboard Cite

Hepatic sinusoidal obstruction syndrome (HSOS) is a hepatic vascular disease presenting with abdominal distension, pain in the hepatic region, ascites, jaundice, and hepatomegaly. In China, this disease is often associated with the oral intake of plants that contain pyrrolidine alkaloids. The existing guidelines are limited to HSOS associated with hematopoietic stem cell transplantation in Western countries. The Hepatobiliary Diseases Committee of the Chinese Society of Gastroenterology convened an expert consensus conference on the diagnosis and treatment of PA–HSOS to evaluate current research in China and abroad. The “Nanjing criteria” developed by the committee to diagnose PA–HSOS include a confirmed history of PA‐containing plant use and (i) abdominal distention and/or pain in the hepatic region, hepatomegaly, and ascites; (ii) elevation of serum total bilirubin or abnormal laboratory liver tests; (iii) evidence on enhanced computed tomography or magnetic resonance imaging; or (iv) pathological evidence that rules out other known causes of liver injury. Supportive symptomatic treatment, anticoagulant therapy, and placement of a transjugular intrahepatic portosystemic shunt for patients who do not respond to medical treatment are effective for the treatment of PA–HSOS. The benefits of glucocorticoids and prostaglandin E1 in PA–HSOS are not clear.

show abstract

Section: Pathologymentioning

confidence: 99%

Section: Imaging Studiesmentioning

confidence: 99%

Section: Pathologymentioning

confidence: 99%

See 1 more Smart Citation

Expert consensus on the clinical management of pyrrolizidine alkaloid‐induced hepatic sinusoidal obstruction syndrome

Zhuge

Liu

Zou

et al. 2019

J of Gastro and Hepatol

127

View full text Add to dashboard Cite

show abstract

“…It was reported that the oral administration of S. aizoon decoction (300-900 g/day), for 3-21 days, were followed by the serious hepatic toxicity, indicated by hepatomegaly, abdominal pain, liver dysfunction, and ascites. The intensity of the symptoms were dose-dependently increased (64).…”

Section: Sedum Aizoon L (Crassulaceae)mentioning

confidence: 90%

Medicinal Plants as Potential Hemostatic Agents

et al. 2020

View full text Add to dashboard Cite

Purpose: Medicinal plants with a variety of phytochemical ingredients remain a potential source for new drug discovery. The use of medicinal herbs in a wide range of diseases and symptoms, such as bleeding, is prevalent in traditional and ethno medicine worldwide. Thus, this work provides a comprehensive review of medicinal plants or their isolated compounds, with respect to their ethno-medicinal use, which have demonstrated the stimulating effect on the hemostasis process. Methods: The relevant studies were withdrawn from electronic databases including Pubmed, EMBASE and Web of Science with a structured search methodology. Results: The total of 17 medicinal plants with hemostatic activity were extracted. The most frequently studied plant families were Compositae, Lamiaceae, Fabaceae, and Asteraceae. Bioactive compounds exerting hemostatic activity included tannins, iridoid glycosides, glycoconjugate, lignan, saponins and phenolic compounds. The most attributed mechanisms include coagulation stimulation via increasing the factor XII activity and plasma fibrinogen levels, the fibrinolysis inhibition, vascular or smooth muscle constriction and platelet aggregation. The most important adverse effects of high dose extract or isolated compounds administration were hepatotoxicity and nephrotoxicity. Conclusion: This review provides a list of medicinal plants with hemostatic activity that could be used as valuable sources of new plant-based hemostatic agents. Furthermore, this could be practical in detecting possible interactions of plants with anticoagulant, antiplatelet, fibrinolytic and antifibrinolytic medications. __________________________________________________________________________________________

show abstract

“…Laboratory examinations of PA-HSOS are not specific. Imaging examinations play an important role in the diagnosis of PA-HSOS [20][21][22] . At present, there is no effective treatment for PA-HSOS.…”

Section: Discussionmentioning

confidence: 99%

Retrospective analysis of the efficacy and safety of rivaroxaban in the treatment of hepatic sinus obstruction syndrome caused by Gynura segetum

Bing

Chang

et al. 2019

Preprint

View full text Add to dashboard Cite

Background PA-HSOS is a rare disease and there is no specific treatment for PA-HSOS. Anticoagulant, antithrombotic and microcirculation therapy can alleviate the progression of PA-HSOS. The application of rivaroxaban in patients with PA-HSOS has not yet been reported. The aim of this study was to analyze the efficacy and safety of rivaroxaban in the treatment of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndromecaused by Gynura segetum (PA-HSOS) . MethodsA retrospective analysis was conducted with the clinical data of patients with PA-HSOS in the acute/subacute phase caused by taking Gynura segetum. The patients were divided into warfarin and rivaroxaban groups according to the anticoagulant therapy they received. Related biochemical indicators were monitored during hospitalization. Liver ultrasound, liver elastography and related biochemical indicators were reviewed every two weeks or one month after discharge. The patients were followed until 1 year after complete remission or death. The efficacy and safety of rivaroxaban was compared with that of warfarin according to the patients' hepatic venous recanalization rates and the occurrence of bleeding events. ResultsThe study included 20 patients, with 10 patients in the warfarin group and 10 patients in the rivaroxaban group. The results showed that the average anticoagulant course in the rivaroxaban group was significantly shorter than that in the warfarin group (P=0.007). With treatment, the remission rates of the rivaroxaban group and the warfarin group reached 90%. There was no significant difference in the incidence of adverse reactions or bleeding events between the two groups (P>0.05). ConclusionsCompared with warfarin, rivaroxaban, a new oral anticoagulant, is convenient and safe for clinical use. It has an obvious effect on PA-HSOS and a low risk of bleeding. It provides a new anticoagulant treatment for PA-HSOS. 4

show abstract

Computed tomography findings of hepatic veno-occlusive disease caused by Sedum aizoon with histopathological correlation

Cited by 19 publications

References 22 publications

Expert consensus on the clinical management of pyrrolizidine alkaloid‐induced hepatic sinusoidal obstruction syndrome

Expert consensus on the clinical management of pyrrolizidine alkaloid‐induced hepatic sinusoidal obstruction syndrome

Medicinal Plants as Potential Hemostatic Agents

Retrospective analysis of the efficacy and safety of rivaroxaban in the treatment of hepatic sinus obstruction syndrome caused by Gynura segetum

Contact Info

Product

Resources

About